ATYR
Price:
$3.27
Market Cap:
$291.04M
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase fo...[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
ATYR
According to aTyr Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.09. This represents a change of 25.35% compared to the average of -3.26 of the last 4 quarters.
The mean historical PE Ratio of aTyr Pharma, Inc. over the last ten years is -0.96. The current -4.09 PE Ratio has changed 42.55% with respect to the historical average. Over the past ten years (40 quarters), ATYR's PE Ratio was at its highest in in the March 2020 quarter at 1.70. The PE Ratio was at its lowest in in the December 2024 quarter at -5.00.
Average
-0.96
Median
-0.61
Minimum
-4.20
Maximum
-0.04
Discovering the peaks and valleys of aTyr Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 880.14%
Maximum Annual PE Ratio = -0.04
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -4.20
Year | PE Ratio | Change |
---|---|---|
2024 | -4.20 | 128.14% |
2023 | -1.84 | 69.72% |
2022 | -1.08 | 10.93% |
2021 | -0.98 | 0.08% |
2020 | -0.98 | 297.14% |
2019 | -0.25 | 129.32% |
2018 | -0.11 | 62.18% |
2017 | -0.07 | 30.75% |
2016 | -0.05 | 23.98% |
2015 | -0.04 | 880.14% |
The current PE Ratio of aTyr Pharma, Inc. (ATYR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.37
5-year avg
-1.82
10-year avg
-0.96
aTyr Pharma, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like aTyr Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like aTyr Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is aTyr Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for aTyr Pharma, Inc. (ATYR)?
What is the highest PE Ratio for aTyr Pharma, Inc. (ATYR)?
What is the 3-year average PE Ratio for aTyr Pharma, Inc. (ATYR)?
What is the 5-year average PE Ratio for aTyr Pharma, Inc. (ATYR)?
How does the current PE Ratio for aTyr Pharma, Inc. (ATYR) compare to its historical average?